Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma

Cancer

Volumn 85, Issue 11, 1999, Pages 2336-2339

  Partyka, Susan ^a   Dumas, Pamela ^a   Ajani, Jaffer ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Advanced solid tumors; Combination chemotherapy; Gastric carcinoma; Granulocyte macrophage colony stimulating factor; Neutropenia

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 0033152622     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2336::AID-CNCR6>3.0.CO;2-I     Document Type: Article

References (18)

1. Parker SL, Tong T, Boldam, Wingo PA. Cancer statistics 1997. CA Cancer J Clin 1997;47:5-27.
2. In: Pazdur R, Coia L, Hoskins W, Wayman L, editors. Cancer management: a multidisciplinary approach. 1st edition., 1996:87-95.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
4. Pyrhonen S, Kuitunen T, Kouri M. A randomized, phase II trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer [abstract]. Ann Oncol 1992;3(Suppl):12.
5. Glimelius B, Hoffmann K, Haglund U, Nyrén O, Sjödén PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-190.
6. Scheithauer W, Komek G, Zeh B, et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer [abstract]. A randomized trial. Presented at the Second International Conference on Biology, Prevention, and Treatment of Gastrointestinal Malignancy, Koln, Germany, 1995:68.
7. Wilke H, Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer: a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 1990;8:65-70.
8. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990;8:147-59.
9. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.
10. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, et al. 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-6.
11. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin. JAMA 1985; 253:2061-7.
12. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
13. Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate (MTX) and 5-fluorouracil (F), combined with Adriamycin (A) (FAMTX) in advanced measurable gastric cancer. J Clin Oncol 1986;4: 1799-803.
14. Neri B, Gemelli MT, Pantalone D, Andreoli F, Bruno S, Fabbroni S, et al. Epidoxorubicin and high dose leucovorin plus 5-fluorouracil in advanced gastric cancer: a phase II study. Anticancer Drugs 1993;4:323-6.
15. di Bartolomeo M, Bajetta E, de Braud F, Bochicchio AM, Gebbia V, Bozzetti F, et al. Phase II study of etoposide, leucovorin, and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology 1995;52:41-4.
16. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A Phase II randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
17. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinoma. A Phase II trial with prognostic factor analyses. Eur J Cancer 1994;30A: 1263-9.
18. Lacave AJ, Barón FJ, Antón LM, Estrada E, De Sande LMG, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer. A Phase II trial. Ann Oncol 1991;2:751-4.